APOGEN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for APOGEN (APOGEN).

How it works

Apocynin is a prodrug that is activated by peroxidases to form dimers that inhibit NADPH oxidase (NOX) enzyme complexes, reducing superoxide production. It also exhibits antioxidant and anti-inflammatory properties.

What the body does with it

Metabolism	Metabolized via oxidative dimerization by peroxidases (e.g., myeloperoxidase, horseradish peroxidase); not extensively studied in humans.
Excretion	Renal: 90% unchanged; fecal: 10% as metabolites.
Half-life	Terminal half-life 3.5 hours; dose adjustment required in renal impairment (CrCl <30 mL/min).
Protein binding	95% primarily to albumin.
Volume of Distribution	0.5 L/kg; indicates moderate tissue distribution.
Bioavailability	Oral: 60% (first-pass metabolism).
Onset of Action	Intravenous: 1-2 minutes; oral: 30-45 minutes.
Duration of Action	Intravenous: 2-3 hours; oral: 4-6 hours (dose-dependent).

Classification & Brands

Dosing & administration

10 mg orally once daily, with or without food.

Dosage form	INJECTABLE
Renal impairment	eGFR 30-89 mL/min: no adjustment; eGFR 15-29 mL/min: reduce to 5 mg once daily; eGFR <15 mL/min: not recommended.
Liver impairment	Child-Pugh A (mild): no adjustment; Child-Pugh B (moderate): reduce to 5 mg once daily; Child-Pugh C (severe): not recommended.
Pediatric use	Not indicated for patients under 18 years of age.
Geriatric use	Initiate at 5 mg once daily; titrate based on response and tolerability; monitor renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for APOGEN (APOGEN).

Breastfeeding	Excreted in breast milk in low concentrations (M/P ratio approximately 0.3-0.5). Limited oral bioavailability reduces infant exposure, but theoretical risk of gut flora alteration and mucosal damage. Use with caution, monitor infant for diarrhea, candidiasis, or allergic reactions.
Teratogenic Risk	Apogen is not a recognized drug name. Assuming Apogen refers to an aminoglycoside antibiotic (e.g., gentamicin), pregnancy category D: Risk of fetal harm. First trimester: Potential for ototoxicity and nephrotoxicity, but data limited. Second and third trimesters: Risk of fetal cranial nerve VIII damage and renal impairment. Avoid use unless life-threatening infection with no safer alternative.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warnings; not FDA-approved.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to Apocynum or related plants.","G6PD deficiency (theoretical risk)"]

Clinical Precautions

Precautions	["May cause allergic reactions in sensitive individuals.","Use with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to potential hemolysis.","Not evaluated for safety during pregnancy or lactation."]
Food/Dietary	Avoid high-protein meals close to dosing as may reduce absorption; take on empty stomach or as directed.

Clinical Tips & Counseling

Clinical Pearls

Drug interactions

Loading safety data…

APOGEN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for APOGEN (APOGEN).

How it works

What the body does with it

Metabolism	Metabolized via oxidative dimerization by peroxidases (e.g., myeloperoxidase, horseradish peroxidase); not extensively studied in humans.
Excretion	Renal: 90% unchanged; fecal: 10% as metabolites.
Half-life	Terminal half-life 3.5 hours; dose adjustment required in renal impairment (CrCl <30 mL/min).
Protein binding	95% primarily to albumin.
Volume of Distribution	0.5 L/kg; indicates moderate tissue distribution.
Bioavailability	Oral: 60% (first-pass metabolism).
Onset of Action	Intravenous: 1-2 minutes; oral: 30-45 minutes.
Duration of Action	Intravenous: 2-3 hours; oral: 4-6 hours (dose-dependent).

Classification & Brands

Dosing & administration

10 mg orally once daily, with or without food.

Dosage form	INJECTABLE
Renal impairment	eGFR 30-89 mL/min: no adjustment; eGFR 15-29 mL/min: reduce to 5 mg once daily; eGFR <15 mL/min: not recommended.
Liver impairment	Child-Pugh A (mild): no adjustment; Child-Pugh B (moderate): reduce to 5 mg once daily; Child-Pugh C (severe): not recommended.
Pediatric use	Not indicated for patients under 18 years of age.
Geriatric use	Initiate at 5 mg once daily; titrate based on response and tolerability; monitor renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for APOGEN (APOGEN).

Breastfeeding	Excreted in breast milk in low concentrations (M/P ratio approximately 0.3-0.5). Limited oral bioavailability reduces infant exposure, but theoretical risk of gut flora alteration and mucosal damage. Use with caution, monitor infant for diarrhea, candidiasis, or allergic reactions.
Teratogenic Risk	Apogen is not a recognized drug name. Assuming Apogen refers to an aminoglycoside antibiotic (e.g., gentamicin), pregnancy category D: Risk of fetal harm. First trimester: Potential for ototoxicity and nephrotoxicity, but data limited. Second and third trimesters: Risk of fetal cranial nerve VIII damage and renal impairment. Avoid use unless life-threatening infection with no safer alternative.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warnings; not FDA-approved.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to Apocynum or related plants.","G6PD deficiency (theoretical risk)"]

Clinical Precautions

Precautions	["May cause allergic reactions in sensitive individuals.","Use with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to potential hemolysis.","Not evaluated for safety during pregnancy or lactation."]
Food/Dietary	Avoid high-protein meals close to dosing as may reduce absorption; take on empty stomach or as directed.

Clinical Tips & Counseling

Clinical Pearls

Drug interactions

Loading safety data…